Towards Precision Allergy Diagnostics
According to the World Health Organization (WHO), by 2050, approximately one in two people worldwide could be affected by some form of allergy, compared with 25% to 30% of the population today (WHO Global Report, May 2025).
Allergic diseases are becoming increasingly prevalent, and sensitization profiles are growing ever more complex. Accurately identifying the allergens involved is therefore essential for effective patient management and treatment decisions.
Against this backdrop, Cerba Laboratory is expanding its allergy testing portfolio with ALEX®3, a next-generation multiplex diagnostic technology.